Are lipid-dependent indicators of cardiovascular risk affected by renal transplantation?

Clinical Transplantation

Volumn 14, Issue 2, 2000, Pages 139-146

  Schena, Antonio ^a   Di Paolo, Salvatore ^a   Morrone, Luigi F ^a   Resta, Francesco ^a   Stallone, Giovanni ^a   Schena, F Paolo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Atherogenic risk; Kidney transplantation; Lipids; Lipoproteins; Lp(a)

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; AZATHIOPRINE; CHOLESTEROL; CREATININE; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN; IMMUNOSUPPRESSIVE AGENT; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; METHYLPREDNISOLONE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGE; ARTICLE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; GENDER; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGE FACTORS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ARTERIOSCLEROSIS; BODY MASS INDEX; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CREATININE; CYCLOSPORINE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIAS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; LINEAR MODELS; LIPOPROTEIN(A); LIPOPROTEINS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; TRIGLYCERIDES;

EID: 0034026539     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2000.140207.x     Document Type: Article

References (53)

1. HILL MN, GROSSMAN RA, FELDMAN HI, HURWITE S, DAFOE DC. Changes in causes of death after renal transplantation, 1966 to 1987. Am J Kidney Dis 1991: 17: 512.
2. KASISKE BL. Atherosclerosis in organ transplant recipients. In: Paul LC, Solez K, eds. Organ Transplantation. Long term results. New York: Marcel Dekker, 1992: 283.
3. AVRAM MM, FEIN PA, ANTIGNANI A et al. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Med 1989: 87: 5.
4. RAINE AEG, CARTER R, MANN JI, CHAPMAN JR, MORRIS PJ. Increase of plasma LDL cholesterol after renal transplantation associated with cyclosporine immunosuppression. Transplant Proc 1987: 19: 1820.
5. SEGOLONI GP, TRIOLO G, GASSADER M et al. Dyslipidemia in renal transplantation: a 3-year follow-up. Transplant Proc 1993: 25: 2178.
6. AVERNA MR, BARBAGALLO CM, SPARACINO V et al. Follow-up of lipid and apoprotein levels in renal transplant recipients. Nephron 1991: 58: 255.
7. DIVAKAR D, BAILEY RR, FRAMPTON CM, GEORGE PM, WALMSLEY TA, MURPHY J. Hyperlipidemia in stable renal transplant recipients. Nephron 1991: 59: 423.
8. SCANN AM, FLESS GM. Lipoprotein(a). Heterogeneity and biological relevance. J Clin Invest 1990: 85: 1709.
9. RADER DJ, BREWER HB JR. Lipoprotein(a): clinical approach to a unique atherogenic lipoprotein. JAMA 1992: 267: 1109.
10. UTERMANN G. The mysteries of lipoprotein(a). Science 1989: 246: 904.
11. GAW A, HOBBS HH. Molecular genetics of lipoprotein(a): new pieces to the puzzle. Curr Opin Lipidol 1994: 5: 149.
12. WEBB AT, REAVELEY DA, O'DONNELL M, O'CONNOR B, SCED M, BROWN EA. Does cyclosporin increase lipoprotein(a) concentration in renal transplant recipients? Lancet 1993: 341: 268.
13. KRAFT HG, SANDHOLZER C, MENZEL HJ, UTERMANN G. Apolipoprotein(a) alleles determine lipoprotein(a) particle density and concentration in plasma. Arterioscler Thromb 1992: 12: 302.
14. MBWU A, DURRINGTON PN. Lipoprotein(a): structure properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990: 85: 1.
15. ETINGIN OR, HAJJAR DP, HAJJAR KA, HARPEL P, NACHMAN RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991: 266: 2459.
16. RIDKER PM, HENNEKENS CH, STAMPFER MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993: 270: 2195.
17. RESTA F, COLACICCO AM, VESPERTINO E et al. Serum lipoprotein(a) increases with aging. Atherosclerosis 1994: 109: 278.
18. THILLET J, DOUCET C, CHAPMAN J, HERBETH B, COHEN D, FAURE-DELANEF L. Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity: evidence from a large population of French centenarians. Atherosclerosis 1998: 136 (2): 389.
19. CRESSMAN MD, HEYKA RJ, PAGANINI EP, O'NEIL J, SKIBINSKI CI, HOFF HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992: 86: 475.
20. KRONENBERG F, KATHREIN H, KONIG P et al. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 1994: 14: 1405.
21. AZROLAN N, BROWN CD, THOMAS L et al. Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL) and lipoprotein(a) levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL and the evaluation of Lp(a) concentrations in hemodialysis patients. Arterioscler Thromb 1994: 14: 1393.
22. KRONENBERG F, KONIG P, LHOTTA K et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentration after renal transplantation. Arterioscler Thromb 1994: 14: 1399.
23. BITTAR AE, RATCLIFFE PJ, RICHARDSON AJ et al. The prevalence of hyperlipidemia in renal transplant recipients: associations with immunosuppressive and antihypertensive therapy. Transplantation 1990: 50: 987.
24. ABDULMASSIH Z, CHEVALIER A, BADER C, DRUEKE T, KREIS H, LACOUR B. Role of lipid disturbances in the atherosclerosis of renal transplant patients. Clin Transplant 1992: 6: 106.
25. 2. Clin Chem 1983: 23: 2026.
26. FRIEDEWALD WT, LEVY RI, FREDRICKSON DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972: 18: 499.
27. GEROLDI D, BELLOTTI V, BUSCAGLIA P et al. Characterization of apo(a) polymorphism by a modified immunoblotting technique in an Italian population sample. Clin Chim Acta 1993: 221: 159.
28. KOCH M, KUTKUHN B, TRENKWALDER E et al. Apolipoprotein B, fibrinogen, HDL cholesterol and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997: 8: 1889.
29. ARO A, SOIMAKALLIO S, VOUTILAINEN E et al. Serum lipoprotein lipid and apoprotein levels as indicators of the severity of angiographically assessed coronary artery disease. Atherosclerosis 1986: 62: 219.
30. MASSY ZA, KASISKE L. Post-transplant hyperlipidemia: mechanisms and management. J Am Soc Nephrol. 1996: 7: 971.
31. MARKELL MS, ARMENTI V, DANOVITCH G, SUMRANI N. Hyperlipidemia and glucose intolerance in the post-renal transplant patient. J Am Soc Nephrol 1994: 4: 937.
32. HILBRANDS LB, DEMACKER NM, HOITSMA J, STALENHOEF FH, KOENE AP. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995: 5: 2073.
33. KOBAYASHI N, OKUBO M, MARUNO F, UCHIDA H, ENDO T, NAKAMURA H. De novo development of hypercholesterolemia and elevated high-density lipoprotein cholesterol: apoprotein A-1 ratio in patients with chronic renal failure following kidney transplantation. Nephron 1983: 35: 237.
34. MAHLEY RW, GRAY ME, HAMILTON RL, QUIRE VS. Lipid transport in liver. Electron microscopy and biochemical studies of alterations in lipoprotein transport induced by cortisone in the rabbit. Lab Invest 1968: 19: 358.
35. KASISKE BL, GUIJARRO C, MASSY ZA, WEIDERKEHR MR, MA JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996: 7: 158.
36. INTERNATIONAL LIPID INFORMATION BUREAU. The ILIB lipid handbook for Clinical Practice. Blood Lipids and Coronary Heart Disease. International Lipid Information Bureau, USA, 1995.
37. KUSTER GM, DREXEL H, BINSWANGER U, AMANN FW. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 1994: 57: 1479.
38. DI PAOLO S, GRANDALIANO G, GESLIALDO L, RANIERI E, SCHENA FP. Low Density Lipoproteins enhance TGF-β1 and MCP-1 expression induced by cyclosporine in human mesangial cells. Clin Exp Immunol 1999: 117: 365.
39. JAVIER NIETO F, ADAM E, SORLIE P et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996: 94: 922.
40. GURA T. Infections: a cause of artery-clogging plaques? Science 1998: 281: 35.
41. DIMENY E, HULTBERG B, WAHLBERG J, FELLSTROM B, ARNADOTTIR M. Serum total homocysteine concentration does not predict outcome in renal transplant recipients. Clin Transplant 1998: 12: 563.
42. DUCLOUX D, RUEDIN C, GIBEY R et al. Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients. Nephrol Dial Transplant 1998: 13: 2890.
43. CRAIG W, POULIN S, BOSTOM A et al. Further characterization of the plasma lipoprotein(a) distribution. J Clin Lab Anal 1995: 9: 392.
44. GAW A, BROWN EA, FORD I. Impact of apo(a) length polymorphism and the control of plasma Lp(a) concentration: evidence for a threshold effect. Arterioscler Thromb Vasc Biol 1998: 18: 1870.
45. KRONENBERG F, STEINMETZ A, KOSTNER GM, DIEPLINGER H. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci 1996: 33: 495.
46. KRONENBERG F, UTERMANN G, DIEPLINGER H. Lipoprotein(a) in renal disease. Am J Kidney Dis 1996: 27: 1.
47. LACKNER C, BOERWINKLE E, LEFFERT CC, RAHMIGT T, HOBBS HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991: 87: 2153.
48. RADER DJ, CAIN W, ZECH LA, USHER D, BREWER HB. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993: 91: 443.
49. THOMAS ME, FREESTONE A, VARGHESE Z, PERSAUD JW, MOORHEAD JF. Lipoprotein(a) in patients with proteinuria. Nephrol Dial Transplant 1992: 7: 597.
50. AUGUET T, SENTÌ M, RUBIÉS-PRAT J et al. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving hemodialysis: influence of apolipoprotein(a) genetic polymorphism. Nephrol Dial Transplant 1993: 8: 1099.
51. SIGURDSON G, BALDURSTDOTTIR A, SIGVALDSON H et al. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992: 69: 1251.
52. SCANU AM. Lipoprotein(a): a potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med 1988: 112: 1045.
53. TITUS K. New focus on 'normal' LDL levels may allow development of cardiac disease risk prediction. JAMA 1996: 276: 934.